BRANFORD, Conn., Nov. 5, 2021 /PRNewswire/ -- IsoPlexis
Corporation (NASDAQ: ISO), the leader in functional
single-cell proteomics, today announced that data generated on its
IsoLight® and IsoSpark® Platforms will be presented at the
35th Annual Meeting of the Society for
Immunotherapy of Cancer (SITC), on November
11th virtually and at the Walter E. Washington
Convention Center in Washington,
DC.
At SITC, IsoPlexis will reveal data outlining how to leverage
certain powerful, proteomically active single cells and their
genetic drivers, identified simultaneously via single-cell
transcriptomics and proteomics analyses on its new Duomic platform.
It is now known that these powerful single-cell subsets of highly
functional "superhero" cells are critical to driving longer term
response in cell and immune therapies via functional proteins. The
SITC presentation will highlight data on how to fully leverage
these superhero cells for clinical CAR-T studies and preclinical
development, clinical combination checkpoint inhibitor studies, and
immune therapy discovery.
The presentation is titled "Emerging standard single cell
functional biomarkers of immune function and potency, and Duomic, a
novel simultaneous single cell transcriptomics and functional
proteomics platform to transform connected therapeutic biology" and
it will take place on Thursday, November
11 from 12:15 - 1:15 p.m. in
Meeting room 204ABC.
Conference attendees can experience the IsoPlexis platform
hands-on by visiting the IsoPlexis Booth (#7). In-booth
presentations will be presented on Friday,
November 12 and Saturday, November
13.
In particular, IsoPlexis will present data leveraging the highly
functional superhero cells:
- For clinical CAR-T studies and preclinical development, which
includes cell therapy response and relapse metrics for advanced
cell therapy and guidance for engineering iterations in cell
therapy manufacturing workflows
- For clinical combination checkpoint inhibitor studies, which
includes circulating T cell single-cell functional proteomics-based
biomarkers uncovering the earliest signs of treatment efficacy
against cancer
- For connected biology accelerating immune therapy discovery,
which includes revelatory first-of-its-kind cellular immune therapy
data and tumor biology data from their Duomic platform which
combines the power of single-cell functional proteomics with the
transcriptomic drivers of these cells, to enable discovery of
better therapeutics and better pathways driving those therapeutics
for the advancement of a whole new class of medicines.
About IsoPlexis
IsoPlexis is leading a new era of functional proteomics. By
identifying our most proteomically active single cells (or
"superhero cells") for the first time, IsoPlexis enables
researchers to connect more directly to in
vivo biology and develop more precise and personalized
therapies. IsoPlexis has been named Top Innovation or Design by The
Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple
others. The IsoPlexis platform is used globally by researchers,
including those at the top 15 global pharmaceutical companies and
at the majority of leading U.S. comprehensive
cancer centers.
Cautionary Note Regarding Forward Looking Statements
Certain statements in this press release are forward-looking
statements that are subject to risks and uncertainties that could
cause results to be materially different than expectations.
Important factors that could cause actual results to differ
materially include: the rate of adoption of the Company's
technology by its customers and potential customers as well as the
risk factors set forth in the Risk Factors section of the Company's
registration statement on Form s-1 filed with the SEC. These
forward-looking statements are not guarantees of future performance
and speak only as of the date hereof, and, except as required by
law, IsoPlexis disclaims any obligation to update these
forward-looking statements to reflect future events or
circumstances.
Investor Contact
investors@isoplexis.com
Press Contact
press@isoplexis.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/isoplexis-to-present-data-at-sitc-2021-connecting-genetic-drivers-to-functional-proteomics-301417469.html
SOURCE IsoPlexis